Immunocore stock faces USD 56.38 target 91.97 percent above price

Published on 10/15/2026 at 20:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immunocore is estimated to report third-quarter results on November 5, 2026. IMCR stock costs EUR 26.20 on October 15, 2026, up 3.60 percent on Nasdaq.

Consensus target and reporting date

MarketBeat listed a USD 56.38 consensus target for Immunocore on October 14, 2026.
Immunocore is estimated to report third-quarter results on November 5, 2026.
Immunocore stock costs EUR 26.20 at Lang & Schwarz on October 15, 2026 at 8:14 p.m. CEST, while Nasdaq trading was up 3.60 percent on the day.
Immunocore had a USD 1.5 billion market capitalization as of October 15, 2026.

IMCR, US45258D1054, Illustration mit AI erstellt.

MarketBeat reported a USD 56.38 consensus target for Immunocore on October 14, 2026, equal to 91.97 percent above the USD 29.36 Nasdaq price used for the comparison. The target gives investors a dated valuation reference while the stock trades at EUR 26.20 at Lang & Schwarz on October 15, 2026 at 8:14 p.m. CEST.

Results date comes next

MarketBeat estimates that Immunocore will report third-quarter 2026 results on November 5, 2026, before the Nasdaq market opens. The page also lists consensus revenue of USD 152.86 million and consensus earnings per share of minus USD 0.12 for that quarter. The prior-year comparison is USD 103.69 million in revenue and positive USD 0.02 in earnings per share.

Price position and daily range

The Nasdaq listing was at USD 29.36 on October 15, 2026 at 2:24 p.m. ET, up 3.60 percent from the USD 28.34 close of October 14, 2026. Immunocore's 52-week range was USD 27.50 to USD 40.72, placing the current Nasdaq price USD 2.22 above the low and USD 11.36 below the high.

StockTitan reported on October 15, 2026 that Immunocore had dosed the first patient in a Phase 1 trial of IMC-S118AI for type 1 diabetes. This was the company's first clinical candidate focused on autoimmune disease, expanding the pipeline beyond oncology and infectious disease.

Valuation and company size

Immunocore had a market capitalization of USD 1.5 billion on October 15, 2026 and a negative price-to-earnings ratio of 154.52. The finance data also showed no dividend yield. The company develops T cell receptor therapies and markets KIMMTRAK for certain adults with unresectable or metastatic uveal melanoma.

Comparison with peers

IMCR (Nasdaq, USD): 3.60 percent, P/E -154.52, market capitalization USD 1.5 billion

IOVA (Nasdaq, USD): 0.84 percent, P/E -19.75, market capitalization USD 6.5 billion

SERA (Nasdaq, USD): minus 1.45 percent, P/E -3.04, market capitalization USD 78.5 million

Market view for the next session

The combination of a USD 56.38 consensus target, the November 5 reporting date and the USD 27.50 52-week low gives the stock three concrete reference points for the next phase of trading. The euro quotation remains the relevant view for investors trading in Germany, while the Nasdaq listing provides the home-market comparison.

Immunocore stock was trading at EUR 26.20 at Lang & Schwarz on October 15, 2026 at 8:14 p.m. CEST. On Nasdaq, the stock was at USD 29.36 on October 15, 2026 at 2:24 p.m. ET, up 3.60 percent versus the prior close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Immunocore stock.